Dr Guy Goodwin is the Chief Medical Officer at COMPASS Pathways and an Emeritus Professor of Psychiatry at the University of Oxford, UK. His research focuses on the neurobiology and treatment of mood disorders, such as bipolar depression, with a focus on the commercial development of COMP360 psilocybin.
In his role at COMPASS, Dr Goodwin plays a pivotal part in advancing the company’s mission, particularly in developing and clinically applying COMP360 psilocybin therapy for treatment-resistant depression.
He completed his medical degree and DPhil in physiology at the University of Oxford. Following his training in psychiatry, he worked as a Clinical Scientist at the MRC Brain Metabolism Unit in Edinburgh for ten years. His career then took him back to Oxford, where he served as the head of the Department of Psychiatry and later as a senior research fellow. Throughout his career, Dr. Goodwin has maintained a strong focus on the care of outpatients, alongside a deep commitment to research.
His research interests have primarily centred around treating mood disorders, with a special emphasis on understanding their neurobiology through the application of neuroscience and technology. This focus has led him to explore and develop new treatments, notably in the field of psychedelics. His involvement with COMPASS Pathways extends from his early role as an advisor in the Phase IIb clinical trial of psilocybin therapy for treatment-resistant depression to his current position as Chief Medical Officer.
Dr Goodwin is a Fellow of the American College of Neuropsychopharmacology and has held prestigious positions such as President of the British Association for Psychopharmacology and the European College of Neuropsychopharmacology. He is also recognized as a highly cited Thomson Reuters researcher, placing him in the top 1% in his field. Additionally, he holds the position of Medical Director at P1vital, a clinical research and healthcare organization.
Explore more info with a membership (any level)
🧑 Extended profile information
📈 In-depth psychedelic reports (Sprout & Tree)
🪄 Weekly psychedelic research & implementation newsletter (free)